Filing Details
- Accession Number:
- 0001209191-15-063783
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-08-04 18:27:30
- Reporting Period:
- 2015-08-03
- Filing Date:
- 2015-08-04
- Accepted Time:
- 2015-08-04 18:27:30
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
827871 | Eagle Pharmaceuticals Inc. | EGRX | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1469124 | Scott Tarriff | C/O Eagle Pharmaceuticals, Inc. 50 Tice Blvd., Suite 315 Woodcliff Lake NJ 07677 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2015-08-03 | 10,658 | $96.36 | 1,523,254 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-08-03 | 2,342 | $95.39 | 1,520,912 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- These shares were sold pursuant to a Rule 10b5-1 trading plan dated as of June 19, 2015.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $95.79 to $96.755, inclusive. The reporting person undertakes to provide to Eagle Pharmaceuticals, Inc., any security holder of Eagle Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) and in footnote (3).
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $95.02 to $95.70, inclusive.